Glioma Epidemiology in the Central Tunisian Population: 1993-2012

  • Trabelsi, Saoussen (Department of Cytogenetics, Molecular genetics and Reproductive Biology, Farhet Hached University Hospital) ;
  • Brahim, Dorra H'mida-Ben (Department of Cytogenetics, Molecular genetics and Reproductive Biology, Farhet Hached University Hospital) ;
  • Ladib, Mohamed (Department of Neurosurgery, Sahloul University Hospital) ;
  • Mama, Nadia (Department of Radiology, Sahloul University Hospital) ;
  • Harrabi, Imed (Department of Community and Preventive Medicine, Farhet Hached University Hospital) ;
  • Tlili, Kalthoum (Department of Radiology, Sahloul University Hospital) ;
  • Yacoubi, Mohamed Tahar (Department of Cytopathology, Farhet Hached University Hospital) ;
  • Krifa, Hedi (Department of Neurosurgery, Sahloul University Hospital) ;
  • Hmissa, Sihem (Department of Cancer Registry of the Centre of Tunisia, Farhet Hached University Hospital) ;
  • Saad, Ali (Department of Cytogenetics, Molecular genetics and Reproductive Biology, Farhet Hached University Hospital) ;
  • Mokni, Moncef (Department of Cytopathology, Farhet Hached University Hospital)
  • Published : 2014.11.06


Background: Glioma is a heterogeneous central nervous system (CNS) tumor group that encompasses different histological subtypes with high variability in prognosis. The lesions account for almost 80% of primary malignant brain tumors. The aim of this study is to extend our understanding of the glioma epidemiology in the central Tunisian region. Materials and Methods: We analyzed 393 gliomas recorded in cancer registry of central Tunisia from 1993 to 2012. Crude incidence rates (CR) and world age-standardized rates (ASR) were estimated using annual population data size and age structure. Statistic correlations were established using Chi-square and Kaplan-Meier test. Results: Tunisian glioma patients were identified with a mean age at diagnosis of 48 years and 1.5 sex ratio (male/female). During the 19 years period of study the highest incidence value was observed in male group between 1998 and 2002 (CR: 0.28, ASR: 0.3). Incidence results underline increasing high grade glioma occurring in the adulthood in the last period (2007-2012). Median survival was 27 months, with 1-, 2- and 5-year survival rates of 42%, 30% and 26%, respectively. Survival was greater in patients with younger age, lower tumor grade, infratentrial tumor location and undergoing a palliative treatment. Conclusions: This central Tunisia gliomas registry study provides important information that could improve glioma management and healthcare practice.


  1. Arshad H, Ahmad Z, Hasan SH (2010). Gliomas: correlation of histologic grade, Ki67 and p53 expression with patient survival. Asian Pac J Cancer Prev, 11, 1637-40.
  2. Barchana M, Margaliot M, Liphshitz I (2012). Changes in brain glioma incidence and laterality correlates with use of mobile phones--a nationwide population based study in Israel. Asian Pac J Cancer Prev, 13, 5857-63.
  3. Bhurgri Y, Bhurgri H, Kayani N, et al (2011). Trends and morphology of central nervous system malignancies in Karachi. Asian Pac J Cancer Prev, 12, 2013-7.
  4. Crocetti E, Trama A, Stiller C, et al (2012). Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer, 48, 1532-42.
  5. Davis FG, Malmer BS, Aldape K, et al (2008). Issues of diagnostic review in brain tumor studies: from the Brain Tumor Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev, 17, 484-9.
  6. Dubrow R, Darefsky AS (2011). Demographic variation in incidence of adult glioma by subtype, United States, 1992-2007. BMC Cancer, 11, 325.
  7. Hess KR, Broglio KR, Bondy ML (2004). Adult glioma incidence trends in the United States, 1977-2000. Cancer, 101, 2293-9.
  8. Jazayeri SB, Rahimi-Movaghar V, Shokraneh F, et al (2013). Epidemiology of primary CNS tumors in Iran: a systematic review. Asian Pac J Cancer Prev, 14, 3979-85.
  9. Larjavaara S, Mantyla R, Salminen T, et al (2007). Incidence of gliomas by anatomic location. Neuro Oncol, 9, 319-25.
  10. Louis DN, Holland EC, Cairncross JG (2001). Glioma classification: a molecular reappraisal. Am J Pathol, 159, 779-86.
  11. Louis DN, Ohgaki H, Wiestler OD, et al (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 114, 97-109.
  12. Manoharan N, Julka PK, Rath GK (2012). Descriptive epidemiology of primary brain and CNS tumors in Delhi, 2003-2007. Asian Pac J Cancer Prev, 13, 637-40.
  13. Mehrazin M, Rahmat H, Yavari P (2006). Epidemiology of primary intracranial tumors in Iran, 1978-2003. Asian Pac J Cancer Prev, 7, 283-8.
  14. Micheli A, Ciampichini R, Oberaigner W, et al (2009). The advantage of women in cancer survival: An analysis of EUROCARE-4 data. Eur J Cancer, 45, 1017-27.
  15. Missaoui N, Trabelsi A, Parkin DM, et al (2010). Trends in the incidence of cancer in the Sousse region, Tunisia, 1993-2006. Int J Cancer, 127, 2669-77.
  16. Ohgaki H, Kleihues P (2005). Epidemiology and etiology of gliomas. Acta Neuropathol, 109, 93-108.
  17. Schwartzbaum JA, Fisher JL, Aldape KD, et al (2006). Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol, 2, 494-503.

Cited by

  1. Insights into the clinical value of cyclin-dependent kinase 5 in glioma: a retrospective study vol.13, pp.1, 2015,
  2. S100A4 Expression is Closely Linked to Genesis and Progression of Glioma by Regulating Proliferation, Apoptosis, Migration and Invasion vol.16, pp.7, 2015,
  3. Long non-coding RNA RP5-833A20.1 inhibits proliferation, metastasis and cell cycle progression by suppressing the expression of NFIA in U251 cells vol.14, pp.6, 2016,
  4. Celastrus orbiculatus extract inhibits the migration and invasion of human glioblastoma cells in vitro vol.16, pp.1, 2016,
  5. Central, Extraventricular and Atypical Neurocytomas: a Clinicopathologic Study of 35 Cases from Pakistan Plus a Detailed Review of the Published Literature vol.17, pp.3, 2016,
  6. Induction of S-Phase Arrest in Human Glioma Cells by Selenocysteine, a Natural Selenium-Containing Agent Via Triggering Reactive Oxygen Species-Mediated DNA Damage and Modulating MAPKs and AKT Pathways vol.41, pp.6, 2016,
  7. Molecular Diagnostic and Prognostic Subtyping of Gliomas in Tunisian Population vol.54, pp.4, 2017,